Adverse Reaction, Breast Cancer, Chemotherapy, Efficacy, Neoadjuvant Therapy, Vitamin D
Conditions
Keywords
Vitamin D, Breast Cancer, Adverse Reaction, Efficacy
Brief summary
This randomized controlled Phase III trial was designed to evaluate the impact of supplemental vitamin D (VD) on the efficacy and side effects of neoadjuvant therapy in patients with breast cancer.
Detailed description
This is a parallel-group, open-label randomized controlled trial designed to investigate the effects of supplemental vitamin D (VD) on the outcomes and side effects of neoadjuvant therapy in patients with breast cancer. Both groups will receive standard neoadjuvant therapy on day 1 and for each subsequent cycle. Additionally, vitamin D2 will be randomly administered to both groups.Blood samples and imaging results will be collected and analyzed prior to the initiation of neoadjuvant therapy and after every two cycles. Key outcomes to be recorded include the pathological complete response rate (pCR), objective response rate (ORR), disease control rate (DCR), and grade III or higher adverse effects related to neoadjuvant therapy. The primary and secondary study findings, along with adverse events, will be thoroughly evaluated.
Interventions
DRUGNeoadjuvant therapy + vitamin D2
Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
DRUGNeoadjuvant therapy
Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
Sponsors
Jiuda Zhao
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age between 18 and 80 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 2. Primary diagnosis of breast cancer confirmed by preoperative pathological examination. 3. Serum 25(OH)D levels less than 20 ng/ml (50 nmol/L). 4. Patients who have not previously received chemotherapy and who plan to undergo at least 4 cycles of 5.neoadjuvant chemotherapy or combined targeted therapy. 6.Life expectancy of at least 6 months. 7.No other uncontrolled benign diseases at the time of recruitment. 8.All patients must have complete clinical medical records. 9.Willingness to voluntarily sign an informed consent form.
Exclusion criteria
1. History of invasive breast cancer. 2. Prior systemic treatment for the treatment or prevention of breast cancer. 3. Known allergic reactions to vitamin D or calcium compounds. 4. Comorbidities that may affect vitamin D or calcium balance or bone health. 5. Vitamin D or calcium supplementation in the past 3 months. 6. Presence of other tumors. 7. Pregnant or lactating women. 8. Individuals who do not wish to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The objective response rate | 4-6months | Difference in change in the objective response rate from first to last assessment between two arms |
| The pathological complete response rate | 4-6months | Difference in change the pathological complete response rate from first to last assessment between two arms |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The disease control rate | 4-6months | Difference in change the disease control rate rate from first to last assessment between two arms |
| Evaluation of side effects related to neoadjuvant therapy (CTCAE v5.0). | From the initiation of neoadjuvant therapy to 21 days after the last cycle of neoadjuvant therapy. | Side effects of neoadjuvant therapy will be assessed according to the CTCAE v5.0 criteria. |
| Pathological response assessment using the Miller & Payne scoring system in conjunction with residual disease in lymph nodes following neoadjuvant therapy. | 4-6months | The pathological response will be assessed using the Miller & Payne scoring system, considering residual disease in lymph nodes after neoadjuvant therapy. |
Countries
China
Contacts
Primary ContactJiuda Zhao
Outcome results
None listed